Pancreatic Cancer Lawsuit Information: Families Are Filing Pancreatic Cancer Lawsuits Against Diabetic Drug Manufacturers That Failed To Inform Consumers and Doctors About Pancreatic Cancer Danger by Pancreatic Cancer Lawsuit Lawyer Jason S. Coomer
Diabetics that have been diagnosed with pancreatic cancer and families of diabetics that have died from pancreatic cancer are now filing lawsuits against drug manufacturers that intentional hid pancreatic cancer risks and/or failed to warn of known pancreatic cancer risks. These lawsuits are seeking compensation from large drug manufacturers that made large profits by unlawfully selling dangerous diabetic drugs with known risks. Persons that took diabetic drugs and families that have lost a loved one that took diabetic drugs and died of pancreatic cancer are encouraged to step forward and file lawsuits against these drug manufacturers that made billions of dollars from selling dangerous drugs.
If you have been taking a diabetes drug and have been diagnosed with Pancreatic Cancer or you have lost a loved one that was taking a diabetes drug and was diagnosed with pancreatic cancer, please report the adverse action to the prescribing medical doctor and FDA as soon as possible.
For persons that have been diagnosed with pancreatic cancer or families that have a loved one that has been diagnosed with pancreatic cancer or have lost a loved one from pancreatic cancer, please feel free to send an e-mail message to Pancreatic Cancer Lawyer Jason Coomer.
Diabetes Medications Including Januvia, Janumet, Janumet XR, Juvisync, Onglyza, Kombiglyze XR, Byetta, and Victoza May Cause An Increased Risk of Pancreatic Cancer
Diabetes drugs in the incretin mimetic class may cause an increased health risk of pancreatic cancer and pancreatitis. These incretin diabetes drug include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). These drugs work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal. They are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. Many of these incretin diabetes drugs already include a black box warning regarding thyroid cancer risk, but evidence is growing that these drugs may also create an increased risk of pancreatic cancer.
People that are taking incretin diabetes drugs including: Januvia, Janument, Victoza, Byetta, Onglyza, Tradjenta, Oseni, and other diabetes drugs should be aware of the cancer health risks. If you have been taking a diabetes drug and have been diagnosed with Pancreatic Cancer or you have lost a loved one that was taking a diabetes drug and was diagnosed with pancreatic cancer, please report the adverse action to the prescribing medical doctor and FDA as soon as possible.
Learn About the Granuloma Annulare Over The Counter Treatment.Granuloma annulare is a skin condition that typically appears as a rash with raised bumps arranged in a circle or ring shape. It usually affects people between the ages of four and 34, although it can be seen in people of all ages. The exact cause of granuloma annulare is unknown; however, there are several possible treatments available, including topical over-the-counter remedies.We will discuss the definition, symptoms and causes of granuloma annulare as well as the different types of topical over-the-counter treatments that may be used to help treat this condition.
ReplyDeleteA Python development company in Dubai offers top-tier services for building scalable, secure, and efficient software solutions. Specializing in web development, automation, data analysis, and machine learning, these companies use Python’s versatility to create customized solutions tailored to client needs. With a python development company dubai, businesses can leverage the power of modern technology to streamline operations, boost productivity, and enhance their digital platforms, all while benefiting from the region's expertise and innovation
ReplyDelete